GLP-1 Signaling in Truncally Vagotomized Subjects

• Status: Unknown status
• Trial end date: 2018-10-01
• Target enrollment: 0
• Participant gender: Male

Summary

Investigation of the importance of vagal signaling for the glucohomeostatic effects of GLP-1. The study will include physiological studies of truncally vagotomized participants and matched controls.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University of Copenhagen
• Collaborator: Rigshospitalet, Denmark
• Treatments: Glucagon-Like Peptide 1; Sitagliptin Phosphate

Criteria

Truncally vagotomized individuals:

Inclusion Criteria:

• Normal fasting plasma glucose

• Normal haemoglobin concentration

• Cardiaresection with a pyloroplasty

• Informed consent

Exclusion Criteria:

• Diabetes mellitus

• Disposition for diabetes mellitus

• Intestinal disease (apart from cardia resection+pyloroplasty)

• Disposition of inflammatory bowel disease

• Intestinal resection (apart from cardia resection+pyloroplasty)

• Body mass index (BMI) > 27,5 kg/m2

• Tobacco use

• Nephropathy (se-creatinine> 130 µM and/or albuminuria)

• Liver disease (ALAT and/or ASAT >2 × refference value)

• known heart condition

• medicinal use, that may not be paused for 12 hours

• Obstipation

• swallowing difficulties

• previous problems with intestinal tube placement

• Latex allergy

• Fructose malabsorption

• Known diseases in the pharynx

• Previous facial or cranial fractures

• Sinusitis

• Bleeding diathesis

Matched controls:

Inclusion Criteria:

• Normal fasting plasma glucose

• Normal haemoglobin concentration

• Informed consent

Exclusion Criteria:

• Cardiaresection with a pyloroplasty

• Diabetes mellitus

• Disposition for diabetes mellitus

• Intestinal disease (apart from cardia resection+pyloroplasty)

• Disposition of inflammatory bowel disease

• Intestinal resection tarmresektion (apart from cardia resection+pyloroplasty)

• Body mass index (BMI) > 27,5 kg/m2

• Tobacco use

• Nephropathy (se-creatinine> 130 µM and/or albuminuria)

• Liver disease (ALAT and/or ASAT >2 × refference value)

• known heart condition

• medicinal use, that may not be paused for 12 hours

• Obstipation

• swallowing difficulties

• previous problems with intestinal tube placement

• Latex allergy

• Fructose malabsorption

• Known diseases in the pharynx

• Previous facial or cranial fractures

• Sinusitis

• Bleeding diathesis